In a statement, Strides said it will “immediately launch” its generic Molnupiravir, indicated for high-risk adult patients with Covid under the brand Stripiravir.
Bengaluru pharma company Strides Pharma Science Limited said that it has received Emergency Use Authorisation from the Drug Controller General of India (DCGI) to launch Molnupiravir, an oral medication for Covid-19 in India.
In a statement, Strides said it will “immediately launch” its generic Molnupiravir, indicated for high-risk adult patients with Covid under the brand Stripiravir. The company is commercialising the product with a group-integrated supply chain for active pharmaceutical ingredients and solid oral dosage from its large-scale WHO pre-qualified manufacturing capacities, the company stated.